Cargando…

In Vivo Mitochondrial Function in Idiopathic and Genetic Parkinson’s Disease

Parkinson’s disease (PD) is associated with brain mitochondrial dysfunction. High-energy phosphates (HEPs), which rely on mitochondrial functioning, may be considered potential biomarkers for PD. Phosphorus magnetic resonance spectroscopy ((31)P-MRS) is a suitable tool to explore in vivo cerebral en...

Descripción completa

Detalles Bibliográficos
Autores principales: Dossi, Gabriele, Squarcina, Letizia, Rango, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023121/
https://www.ncbi.nlm.nih.gov/pubmed/31905632
http://dx.doi.org/10.3390/metabo10010019
_version_ 1783498176107380736
author Dossi, Gabriele
Squarcina, Letizia
Rango, Mario
author_facet Dossi, Gabriele
Squarcina, Letizia
Rango, Mario
author_sort Dossi, Gabriele
collection PubMed
description Parkinson’s disease (PD) is associated with brain mitochondrial dysfunction. High-energy phosphates (HEPs), which rely on mitochondrial functioning, may be considered potential biomarkers for PD. Phosphorus magnetic resonance spectroscopy ((31)P-MRS) is a suitable tool to explore in vivo cerebral energetics. We considered 10 (31)P-MRS studies in order to highlight the main findings about brain energetic compounds in patients affected by idiopathic PD and genetic PD. The studies investigated several brain areas such as frontal lobes, occipital lobes, temporoparietal cortex, visual cortex, midbrain, and basal ganglia. Resting-state studies reported contrasting results showing decreased as well as normal or increased HEPs levels in PD patients. Functional studies revealed abnormal PCr + βATP levels in PD subjects during the recovery phase and abnormal values at rest, during activation and recovery in one PD subject with PINK1 gene mutation suggesting that mitochondrial machinery is more impaired in PD patients with PINK1 gene mutation. PD is characterized by energetics impairment both in idiopathic PD as well as in genetic PD, suggesting that mitochondrial dysfunction underlies the disease. Studies are still sparse and sometimes contrasting, maybe due to different methodological approaches. Further studies are needed to better assess the role of mitochondria in the PD development.
format Online
Article
Text
id pubmed-7023121
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70231212020-03-12 In Vivo Mitochondrial Function in Idiopathic and Genetic Parkinson’s Disease Dossi, Gabriele Squarcina, Letizia Rango, Mario Metabolites Review Parkinson’s disease (PD) is associated with brain mitochondrial dysfunction. High-energy phosphates (HEPs), which rely on mitochondrial functioning, may be considered potential biomarkers for PD. Phosphorus magnetic resonance spectroscopy ((31)P-MRS) is a suitable tool to explore in vivo cerebral energetics. We considered 10 (31)P-MRS studies in order to highlight the main findings about brain energetic compounds in patients affected by idiopathic PD and genetic PD. The studies investigated several brain areas such as frontal lobes, occipital lobes, temporoparietal cortex, visual cortex, midbrain, and basal ganglia. Resting-state studies reported contrasting results showing decreased as well as normal or increased HEPs levels in PD patients. Functional studies revealed abnormal PCr + βATP levels in PD subjects during the recovery phase and abnormal values at rest, during activation and recovery in one PD subject with PINK1 gene mutation suggesting that mitochondrial machinery is more impaired in PD patients with PINK1 gene mutation. PD is characterized by energetics impairment both in idiopathic PD as well as in genetic PD, suggesting that mitochondrial dysfunction underlies the disease. Studies are still sparse and sometimes contrasting, maybe due to different methodological approaches. Further studies are needed to better assess the role of mitochondria in the PD development. MDPI 2019-12-28 /pmc/articles/PMC7023121/ /pubmed/31905632 http://dx.doi.org/10.3390/metabo10010019 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dossi, Gabriele
Squarcina, Letizia
Rango, Mario
In Vivo Mitochondrial Function in Idiopathic and Genetic Parkinson’s Disease
title In Vivo Mitochondrial Function in Idiopathic and Genetic Parkinson’s Disease
title_full In Vivo Mitochondrial Function in Idiopathic and Genetic Parkinson’s Disease
title_fullStr In Vivo Mitochondrial Function in Idiopathic and Genetic Parkinson’s Disease
title_full_unstemmed In Vivo Mitochondrial Function in Idiopathic and Genetic Parkinson’s Disease
title_short In Vivo Mitochondrial Function in Idiopathic and Genetic Parkinson’s Disease
title_sort in vivo mitochondrial function in idiopathic and genetic parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023121/
https://www.ncbi.nlm.nih.gov/pubmed/31905632
http://dx.doi.org/10.3390/metabo10010019
work_keys_str_mv AT dossigabriele invivomitochondrialfunctioninidiopathicandgeneticparkinsonsdisease
AT squarcinaletizia invivomitochondrialfunctioninidiopathicandgeneticparkinsonsdisease
AT rangomario invivomitochondrialfunctioninidiopathicandgeneticparkinsonsdisease